Why a Sudoku-solving program looks smart: Recursion, backtracking, and the idea of 'trying from the most likely failure points'

I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone

Recursion Pharmaceuticals (NasdaqGS:RXRX) said Sanofi has exercised its option on the first immunology candidate in their ...
Nasdaq

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
manilatimes

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Asianet Newsable on MSN

RXRX stock heads for its best day in over a year – what’s driving the rally today?

Sanofi selected its first drug development candidate under its collaboration with Recursion.
MarketScreener

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...